The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I don’t know about the rest of you, but I’m incredibly excited about where Avacta is at the moment.
My view is that in the interims next week (if it is not published before), we will be told that Medusa – as legal owner of AffiDX for home-use – has already secured HUA in the EU.
My view is also that in the interims next week, we will be told that Abingdon is already manufacturing the AffiDX LFT.
I highly doubt we’ll be given any AVA6K data, but I remain very confident that the company will publish very meaningful data before Christmas. Signs next week that all is going well for AVA6K could be further cohorts being dosed; further sites opening; and INDs / CTAs being submitted for the next pre CISION prodrugs.
(A very big!) IF it’s positive, I feel that it will quell much of the panic of a great number of investors (that there evidently are) over the status of AffiDX.
I’m also hopeful of proper updates on the Affimer Therapeutics partnerships, and my fingers are crossed that one of the partnerships (LG Chem?) may be close to bringing an Affimer-based therapeutic into clinic (in 2022?).
Have been holding for coming up to two years now: Q4 2021 will for me be a defining period for Avacta.
For me, the share price is completely disconnected from the tremendous value that’s been rapidly built up – in both divisions – over the past 18 months.
I stated last March, at ~20p, that I thought Avacta was one of those incredibly rare, potential 100 baggers (assuming, of course that pre CISION works in man!). My view on that has not changed whatsoever – in fact, given COVID19, I think it’s much more likely to occur than when I first invested.
If all goes well in AVA6K P1, the most difficult will be to do absolutely nothing.
Best of luck to fellow holders!
Exciting times indeed snd here’s hoping you’re right re news next Thursday!
Why a very big if?
I think the trials would have been canned already if the if is that big.
Thanks for the positivity, Myles - this board could use an extra dose of that right now….
I certainly know nothing more than anyone else - and massively less than most - but (for what it’s worth!) my instincts tell me that Avacta is heading in the right direction, if at an apparently slower speed than most would like.
Those instincts are fed by the excellent research that some posters undertake and generously share with the rest of us, plus the simple gut feeling deriving from watching, reading, listening and trying to learn.
I can only hope my instincts are right.
They have been tested a good deal in the 8 years that I’ve now been invested here - and increasingly so since I put the kitchen sink into this investment!
GLA .
Fingers crossed….
Ladies and gents, this is how it works. The group will now come in, report it and get it removed. Let the green boxes do their thing
With all due respect, I'm not excited and that way I won't be overly disappointed. It's a better strategy for me and it's one I'd advise. Getting to £1bn for a small bio-tech can take some time. I've got the patience which is certainly tested through the volatility. If this is a future Roche then let's see it start delivering
yeah but what about the meeting?
Thanks Myles always appreciate you insight .
I don't know about you Myles, bit I'd be even more excited if the SP was 300p :0))
Yes Myles. Agree. Matches the belief that AS has given up trying to ‘please’ investors with Jam. Binary news only - hence the slide and the new VOC, Tango (troll).
Keep it up mate. I don’t believe you read and let it bother you - but the vile abuse will abate soon enough.
ITM,if you believe you have no choice but to hold….:-)
Thanks for sharing your thoughts Myles.
It would seem there is indeed still a significant market for LFT's - given supply apparently cannot keep up with demand:
"Travel rule change delayed by lateral flow test shortage
Covid testing firms are facing a shortage of lateral flow tests, says Transport Secretary Grant Shapps.
He told MPs this was the reason for delaying the date when PCR tests will be removed for travellers returning to England.
The travel industry has called on the government to confirm when in October the rules will be changed.
Mr Shapps said it would take several weeks to switch from PCR tests to lateral flow tests.
Addressing the Transport Select Committee, he said the Department of Health was responsible for making the decision.
However, he stressed that his colleagues were aware of school half-term dates and understood the speed required to implement this change.
"But my understanding is that the ramp-up of supply of lateral flow [tests] through the private testing sector has some way to go [since] they have been almost entirely been involved in providing PCR [tests] currently," he told MPs.
When questioned by MP Ben Bradshaw about why this was an issue, since many test providers also offer lateral flow tests, Mr Shapps said it was a question of scale.
"We go from a situation where they are providing a low number of thousands [of tests], to probably millions of tests very quickly and need a few weeks to scale up on it," he said.
He added that the extra few weeks were needed for making sure the administrative switch-over when the rules changed went off without a hitch."
https://www.bbc.co.uk/news/business-58656292
coolfree, how do you know they are the same ones?
Jupiter closing its short ?
If you care to read his posts, Myles responded multiple times to the trolls explaining why he still felt that Affidx was going to be huge for AVCT.
I find it difficult to be positive Myles due to the sp action over the past few months. Not quite well off enough to be completely phlegmatic about it. Esp. when I am overweight pharma as a whole and its not been flavour of the last few months. Still like many on this board I am happy to be a bloodyminded large holder and wait for one or more of the large opportunities to come good before even slicing.
Great comments yet again Myles, thank you for sharing your thoughts. Ignore the non-constructive (destructive) comments and keep continue posting either on here or on twitter.
Good update Myles.
Point Biopharma have confirmed the planned timeline for the introduction into the clinic of PNT 2004.
Https://investors.pointbiopharma.com/wp-content/uploads/2021/06/POINT-RACA-Investor-Call-Presentation.pdf
Thank you mstar. Had not seen that document before. Preclinical data looks good. Looking forward to seeing P1 data next year.
“Why is Master Myles trolling the board again?“
You got some front.
Thanks Myles.
LG Chem is looking good if you read their Patent.
There are many patents out there which mention the use of affimer(s) directly or as an option. IMO it certainly won't be long before we see more trials and/or products coming to market.
AS will be presenting to a bunch of investors on 30th and so will RedX in the same session.
They are looking at targeted cancer treatments and are very much a direct competitor of ours.
Having been faced with a similar situation personally at the point of launching our new Distributorship in the US we met up with a couple of guys who were known to us and in the process of doing exactly the same in exactly the same marketplace but with different key principals..so we approached them and merged before we launched..the synergy was amazing...
Would a RedX/Avacta merger be totally out of the question do you think?
Wyndrum, Myles mentioned that he saw a potential 100 bagger from 20p but you'd be more excited at an sp of 300p
I'm far from the brightest but I don't get your logic or is it can't wait won't wait?
I put the kitchen sink into this investment! .. and some .. I put it all on black 13 .. Fingers crossed ..
Oh and RedX also use FDI Consulting...
Grrrr phone...FTI consulting.